trending Market Intelligence /marketintelligence/en/news-insights/trending/9G72IhZuA1BUsTJ-MDsolA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Forty Seven prices $170.1M common stock offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Forty Seven prices $170.1M common stock offering

Forty Seven Inc. priced its public offering of 4,860,000 common shares at $35 per share.

The Menlo Park, Calif.-based immuno-oncology company also granted underwriters a 30-day option to buy up to an additional 729,000 common shares at the same price.

Gross proceeds are expected to be $170.1 million.

The offering is expected to close Dec. 16.

Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC are joint book-running managers for the offering, while Guggenheim Securities LLC and Oppenheimer & Co. Inc. are acting as lead managers. JonesTrading Institutional Services LLC and Roth Capital Partners LLC are co-managers.

Forty Seven develops therapies for cancer. Its blood cancer therapy magrolimab was granted fast-track designation by the U.S. Food and Drug Administration in September.